![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: BTBD16 |
Gene summary for BTBD16 |
![]() |
Gene information | Species | Human | Gene symbol | BTBD16 | Gene ID | 118663 |
Gene name | BTB domain containing 16 | |
Gene Alias | C10orf87 | |
Cytomap | 10q26.13 | |
Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q32M84 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
118663 | BTBD16 | HCC1_Meng | Human | Liver | HCC | 3.44e-29 | 6.78e-02 | 0.0246 |
118663 | BTBD16 | S027 | Human | Liver | HCC | 8.84e-04 | 5.36e-01 | 0.2446 |
118663 | BTBD16 | S028 | Human | Liver | HCC | 1.36e-18 | 5.87e-01 | 0.2503 |
118663 | BTBD16 | S029 | Human | Liver | HCC | 1.18e-18 | 7.41e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BTBD16 | SNV | Missense_Mutation | novel | c.1103N>C | p.Asp368Ala | p.D368A | Q32M84 | protein_coding | deleterious(0) | probably_damaging(0.955) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
BTBD16 | SNV | Missense_Mutation | rs202210822 | c.11C>T | p.Ser4Leu | p.S4L | Q32M84 | protein_coding | tolerated(0.16) | benign(0) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
BTBD16 | SNV | Missense_Mutation | rs753828510 | c.1082N>G | p.His361Arg | p.H361R | Q32M84 | protein_coding | deleterious(0.03) | possibly_damaging(0.656) | TCGA-DF-A2KY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
BTBD16 | SNV | Missense_Mutation | novel | c.139N>G | p.Phe47Val | p.F47V | Q32M84 | protein_coding | tolerated(0.33) | benign(0.075) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BTBD16 | SNV | Missense_Mutation | novel | c.411N>C | p.Glu137Asp | p.E137D | Q32M84 | protein_coding | tolerated(0.15) | possibly_damaging(0.461) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
BTBD16 | SNV | Missense_Mutation | novel | c.464T>C | p.Val155Ala | p.V155A | Q32M84 | protein_coding | deleterious(0) | possibly_damaging(0.654) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
BTBD16 | SNV | Missense_Mutation | c.1061A>T | p.Gln354Leu | p.Q354L | Q32M84 | protein_coding | tolerated(0.12) | benign(0.014) | TCGA-MI-A75G-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
BTBD16 | SNV | Missense_Mutation | c.233G>T | p.Gly78Val | p.G78V | Q32M84 | protein_coding | tolerated(0.36) | benign(0.036) | TCGA-05-4395-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
BTBD16 | SNV | Missense_Mutation | novel | c.1042C>A | p.Pro348Thr | p.P348T | Q32M84 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-55-6969-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
BTBD16 | SNV | Missense_Mutation | c.1147N>T | p.Gly383Trp | p.G383W | Q32M84 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-78-7150-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | carboplatin | PD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |